» Articles » PMID: 28735660

Case Detection and Diagnosis of Primary Aldosteronism - The Consensus of Taiwan Society of Aldosteronism

Abstract

Background/purpose: Even though the increasing clinical recognition of primary aldosteronism (PA) as a public health issue, its heightened risk profiles and the availability of targeted surgical/medical treatment being more understood, consensus in its diagnosis and management based on medical evidence, while recognizing the constraints of our real-world clinical practice in Taiwan, has not been reached.

Methods: The Taiwan Society of Aldosteronism (TSA) Task Force acknowledges the above-mentioned issues and reached this Taiwan PA consensus at its inaugural meeting, in order to provide updated information of internationally acceptable standards, and also to incorporate our local disease characteristics into the management of PA.

Results: When there is suspicion of PA, a plasma aldosterone to renin ratio (ARR) should be obtained initially. Patients with abnormal ARR will undergo confirmatory laboratory and image tests. Subtype classification with adrenal venous sampling (AVS) or NP-59 nuclear imaging, if AVS not available, to lateralize PA is recommended when patients are considered for adrenalectomy. The strengths and weaknesses of the currently available identification methods are discussed, focusing especially on result interpretation.

Conclusion: With this consensus we hope to raise more awareness of PA among medical professionals and hypertensive patients in Taiwan, and to facilitate reconciliation of better detection, identification and treatment of patients with PA.

Citing Articles

Shifting paradigms in primary aldosteronism: reconsideration of screening strategy via integrating pathophysiological insights.

Kitamoto T, Ruike Y, Koide H, Inoue K, Maezawa Y, Omura M Front Endocrinol (Lausanne). 2025; 15:1372683.

PMID: 39877848 PMC: 11772158. DOI: 10.3389/fendo.2024.1372683.


Validating Machine Learning Models Against the Saline Test Gold Standard for Primary Aldosteronism Diagnosis.

Liu J, Huang W, Hu J, Hong N, Rhee Y, Li Q JACC Asia. 2025; 4(12):972-984.

PMID: 39802987 PMC: 11712017. DOI: 10.1016/j.jacasi.2024.09.010.


The relationship between tissue inhibitor of metalloproteinases-1 and KCNJ5 mutation in aldosterone-producing adenoma patients.

Lin N, Chen T, Wu X, Chang Y, Tsai C, Liao C Hypertens Res. 2024; 48(2):563-573.

PMID: 39690251 DOI: 10.1038/s41440-024-02030-w.


Diagnostic efficacy of aldosterone-to-renin ratio to screen primary aldosteronism in hypertension: a systemic review and meta-analysis.

Kao T, Chen J, Liu J, Tseng W, Hsieh C, Wu V Ther Adv Endocrinol Metab. 2024; 15:20420188241303429.

PMID: 39669529 PMC: 11635879. DOI: 10.1177/20420188241303429.


Visceral adiposity as a predictor of new-onset diabetes in patients with primary aldosteronism: a cohort study.

Chu W, Er L, Chang C, Lu J, Wu W, Tsai Y Ther Adv Chronic Dis. 2024; 15:20406223241301892.

PMID: 39619168 PMC: 11607768. DOI: 10.1177/20406223241301892.